Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 15/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768911 | 1.00 | ESR1 (0.43) | ESR1ESR2IGF1RALOX15CYP17A1 | |
| SCHEMBL30769301 | 0.80 | ESR1 (0.43) | ESR1ESR2 | |
| SCHEMBL30769315 | 0.80 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL30769087 | 0.80 | ESR1 (0.43) | ESR1ESR2 | |
| SCHEMBL30769026 | 0.80 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL30769044 | 0.80 | ESR1 (0.43) | ESR1ESR2 | |
| SCHEMBL29966359 | 0.80 | ESR1 (0.45) | ESR1ESR2 | |
| SCHEMBL29966597 | 0.80 | ESR1 (0.45) | ESR1ESR2 | |
| SCHEMBL29092227 | 0.80 | ESR1 (0.47) | ESR1ESR2 | |
| SCHEMBL27081332 | 0.79 | ESR1 (0.44) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |